Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Drug Products: Biologics, Biosimilars and Interchangeables01:28

Drug Products: Biologics, Biosimilars and Interchangeables

223
Body:Biologics, derived from living sources such as humans, animals, or microorganisms, represent a significant category of pharmaceuticals. These complex molecules, developed through advanced biotechnological methods or purified from natural sources, include essential medical treatments like insulin and growth hormones. The complexity of biologics arises from their large molecular structures and the intricate processes required for their production, making them distinct from conventional...
223
Bioequivalence studies: Biowaivers01:13

Bioequivalence studies: Biowaivers

211
Body:In certain scenarios, in vitro dissolution tests can replace in vivo bioequivalence studies. This is particularly true when a drug product, though available in varying strengths, maintains proportional similarity in its active and inactive ingredients. In such cases, the need for in vivo bioequivalence studies for lower strength variants may be waived, provided dissolution tests and in vivo studies on the highest strength yield satisfactory results.Bioequivalence can be indicated through...
211
Bioequivalence: Overview01:16

Bioequivalence: Overview

1.7K
Pharmaceutical equivalents, by definition, are drug products with the same active ingredient in the same quantities, encapsulated in identical dosage forms, and intended for the same administration routes. These pharmaceutical equivalents are deemed bioequivalent if the bioavailability of the active entity in the drug preparations is similar. Moreover, pharmaceutical equivalents demonstrating bioequivalence are also regarded as therapeutically equivalent. This means that when used as directed,...
1.7K
Pharmaceutical Equivalents01:26

Pharmaceutical Equivalents

171
As defined by regulatory standards, pharmaceutical equivalents require generic drug products to have identical dosage forms and chemically identical active pharmaceutical ingredients (APIs). They must adhere to compendial or applicable standards for potency, content uniformity, disintegration times, and dissolution rates. In the case of modified-release dosage forms, variations in drug content are permissible as long as the delivered amount remains consistent with the innovator drug product.
171
Bioequivalence of Drugs: Drugs with Multiple Indications01:09

Bioequivalence of Drugs: Drugs with Multiple Indications

144
The concept of therapeutic equivalence (TE) in drugs with multiple indications is complex. A generic drug may be therapeutically equivalent to a brand-name product for one specific indication, but this doesn't necessarily mean it's equivalent for all other indications. Evidence of TE in one patient group and bioequivalence shown in healthy volunteers can support—but not confirm—TE for other indications. However, definitive proof requires individual clinical studies for each...
144
Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence01:27

Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence

141
Changes in polymorphic forms can significantly influence the bioavailability of poorly soluble drugs. Although the FDA defines pharmaceutical equivalence based on having the same active ingredient, dosage form, and route of administration, it does not automatically disqualify products with different polymorphic forms. This means two products with different polymorphs can still be deemed pharmaceutically equivalent. However, polymorphic differences can affect properties like wettability,...
141

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

The effect of mobile phone messaging to support COVID-19 vaccination in Colombia: A randomized controlled clinical trial.

PLOS global public health·2026
Same author

Diamond-loaded polyimide aerogel scattering filters and their applications in astrophysical and planetary science observations.

The Review of scientific instruments·2026
Same author

Editorial Comment on "Global Disparities in Urological Research: A Systematic Bibliometric Analysis of Low- and Middle-income Country Representation in Urology Journals From 2013-2023".

Urology·2026
Same author

Trends in hospital pricing for vulnerable emergency department users, 2021-2023.

The American journal of managed care·2026
Same author

Concerns regarding "GLP-1RA and the risk of non-arteritic anterior ischaemic optic neuropathy in patients with type 2 diabetes".

Diabetes, obesity & metabolism·2025
Same author

The biosimilar shift: trending infliximab biosimilar utilization and associated cost savings for commercial insurance.

The American journal of managed care·2025
Same journal

Different Clinical Questions Need Different Estimands.

Therapeutic innovation & regulatory science·2026
Same journal

Medicinal Chemistry Perspectives on Drug Repurposing: Innovative Approaches and Therapeutic Breakthrough.

Therapeutic innovation & regulatory science·2026
Same journal

Understanding the Added Value of Action Limits for QTL Monitoring.

Therapeutic innovation & regulatory science·2026
Same journal

Implementing Project Optimus in Oncology Dosage Optimization: Where are We Now?

Therapeutic innovation & regulatory science·2026
Same journal

Validation of the Ontario Protocol Assessment Level (OPAL) Tool for Assessing Clinical Trial Complexity and Supporting Workforce Planning in the Italian Clinical Research Context.

Therapeutic innovation & regulatory science·2026
Same journal

The Effect of Covariate Adjustment for Cox Regression in Cardiovascular Outcome Trials.

Therapeutic innovation & regulatory science·2026
查看所有相关文章

相关实验视频

Updated: Jan 11, 2026

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
07:25

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

Published on: May 4, 2017

18.2K

可互换生物类似品名称的监管要求

Praveen J Samy1, Morgane C Mouslim2,3, Charles L Bennett4

  • 1Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.

Therapeutic innovation & regulatory science
|November 16, 2025
PubMed
概括
此摘要是机器生成的。

自2020年以来,美国食品和药物管理局 (FDA) 已经批准了26种可互换的生物类似药,最近的批准加速. 新的FDA指导可能会进一步简化这一过程,潜在地降低成本并增加生物类似药的采用.

更多相关视频

Laboratory Scale Production and Purification of a Therapeutic Antibody
09:54

Laboratory Scale Production and Purification of a Therapeutic Antibody

Published on: January 24, 2017

18.2K
Author Spotlight: Biological Standardization to Ensure Reproducibility and Harmonization in Research
04:50

Author Spotlight: Biological Standardization to Ensure Reproducibility and Harmonization in Research

Published on: August 4, 2023

1.6K

相关实验视频

Last Updated: Jan 11, 2026

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
07:25

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

Published on: May 4, 2017

18.2K
Laboratory Scale Production and Purification of a Therapeutic Antibody
09:54

Laboratory Scale Production and Purification of a Therapeutic Antibody

Published on: January 24, 2017

18.2K
Author Spotlight: Biological Standardization to Ensure Reproducibility and Harmonization in Research
04:50

Author Spotlight: Biological Standardization to Ensure Reproducibility and Harmonization in Research

Published on: August 4, 2023

1.6K

科学领域:

  • 制药科学 制药科学
  • 监管科学 监管科学
  • 卫生经济学 卫生经济学

背景情况:

  • 美国食品和药物管理局 (FDA) 最初要求进行广泛的III期临床试验,以进行可互换生物类似药的指定.
  • 最近的指导草案 (2024年6月) 将重点从临床数据转移到分析数据,可能会改变批准途径.

研究的目的:

  • 分析2019年至2025年美国可互换生物类似药批准的趋势.
  • 检查可互换生物类似药的制造商战略和监管时间表.
  • 评估FDA不断变化的指导方针对生物类似药开发的影响.

主要方法:

  • 利用FDA紫色书档案 (截至2025年9月) 来识别可互换的生物类似药和相关数据.
  • 分析了按年,制造商,产品类别和提交策略的批准趋势.
  • 根据FDA提交和批准日期计算平均监管批准时间表.

主要成果:

  • 自2020年以来批准的26种可互换的生物类似药;2024年1月至2025年9月期间批准的19种.
  • 阿达利穆马布生物类似药占据了很大一部分 (6项批准).
  • 平均批准时间显著减少,从798天 (2020) 减少到364天 (2024).
  • 同时提交可互换性成为主要策略.

结论:

  • 同时可互换的指定现在是主要的监管途径.
  • 美国食品和药物管理局2024年6月的指导草案可能通过删除切换研究要求来降低开发成本和时间表.
  • 这些监管转变,加上教育,可以促进生物类似药的吸收,降低生物药物成本.